Top

Published in:

01-03-2009 | Clinical study - patient study

Long-term survival in primary CNS lymphoma treated by high-dose methotrexate monochemotherapy: role of STAT6 activation as prognostic determinant

Authors: Seung-Ho Yang, Kun Soo Lee, Il Sup Kim, Jae Taek Hong, Jae Hoon Sung, Byung Chul Son, Sang Won Lee, Yong-Kil Hong

Published in: Journal of Neuro-Oncology | Issue 1/2009

Abstract

We report a single-center experience of 16 immunocompetent patients diagnosed with primary central nervous system lymphoma and treated with monochemotherapy with high-dose methotrexate (MTX) and deferred radiotherapy. MTX was given at a dose of 8.0 g/m² for induction and at a dose of 3.5–8.0 g/m² for maintenance. There were eight complete responses (CR), one partial response, one stable disease, and six patients whose tumors progressed in spite of the chemotherapy. At final follow-up, five of five CRs were alive and well without radiotherapy, with median follow-up of 26 months. Overall survival in eight non-CRs treated with the subsequent radiotherapy was 36 months. In the immunohistochemical study, STAT6 was positively expressed in 8 out of 13 cases. They included all non-CRs and two CRs. This observation suggests that STAT6 expression can be used as a prognostic determinant for MTX chemotherapy.

Tseng MY, Tu YK, Shun CT (1998) Primary central nervous system lymphoma: a retrospective study. J Clin Neurosci 5:409–412. doi:10.1016/S0967-5868(98)90273-9 PubMedCrossRef

Shibamoto Y, Tsuchida E, Seki K, Oya N, Hasegawa M, Toda Y, Takemoto M, Sumi M, Hiratsuka J, Oguchi M, Hosono M, Yasuda S, Sougawa M, Kakutoh Y, Hayabuchi N (2004) Primary central nervous system lymphoma in Japan 1995–1999: changes from the preceding 10 years. J Cancer Res Clin Oncol 130:351–356. doi:10.1007/s00432-004-0547-x PubMedCrossRef

Quek R, Ty A, Lim ST, See S, Wong MC, Yap SP, Sng I, Hee SW, Tao M (2006) Primary central nervous system lymphoma in an Asian population: a 15-year experience. Onkologie 29:455–459. doi:10.1159/000095342 PubMedCrossRef

Schultz C, Scott C, Sherman W, Donahue B, Fields J, Murray K, Fisher B, Abrams R, Meis-Kindblom J (1996) Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphoma: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol 14:556–564PubMed

Guha-Thakurta N, Damek D, Pollack C, Hochberg FH (1999) Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol 43:259–268. doi:10.1023/A:1006210703827 PubMedCrossRef

McAllister LD, Doolittle ND, Guastadisegni PE, Kraemer DF, Lacy CA, Crossen JR, Neuwelt EA (2000) Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46:51–61. doi:10.1097/00006123-200001000-00010 PubMedCrossRef

O’Brien P, Roos D, Pratt G, Liew K, Barton M, Poulsen M, Olver I, Trotter G (2000) Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 18:519–526PubMed

Abrey LE, Yahalom J, De Angelis LM (1997) Relapse and late neurotoxicity in primary central nervous system lymphoma. Neurology 48:A18

Siobhan NG, Rosenthal MA, Ashley D, Cher L (2000) High dose methotrexate for primary CNS lymphoma in the elderly. Neuro Oncol 2:40–44. doi:10.1215/15228517-2-1-40 CrossRef

10.

Bessell EM, Graus F, Lopez-Guillermo A, Lewis SA, Villa S, Verger E, Petit J (2001) CHOP/BVAM regimen plus radiotherapy in patients with primary CNS non Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 50:457–464. doi:10.1016/S0360-3016(01)01451-1 PubMedCrossRef

11.

Lu X, Nechushtan H, Ding F, Rosado MF, Singal R, Alizadeh AA, Lossos IS (2005) Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas. Blood 105:2924–2932. doi:10.1182/blood-2004-10-3820 PubMedCrossRef

12.

Bruns HA, Kaplan MH (2006) The role of constitutively active Stat6 in leukemia and lymphoma. Crit Rev Oncol Hematol 57:245–253. doi:10.1016/j.critrevonc.2005.08.005 PubMedCrossRef

13.

Carey GB, Semenova E, Qi X, Keegan AD (2007) IL-4 protects the B-cell lymphoma cell line CH31 from anti-IgM-induced growth arrest and apoptosis: contributing of the PI-3 kinase/AKT pathway. Cell Res 17:942–955. doi:10.1038/sj.cr.2007.90 PubMedCrossRef

14.

Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial glioma. J Clin Oncol 8:1277–1280PubMed

15.

Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214. doi:10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6PubMedCrossRef

16.

Skinnider BF, Elia AJ, Gascoyne RD, Patterson B, Trumper L, Kapp U, Mak TW (2002) Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 15:618–626. doi:10.1182/blood.V99.2.618 CrossRef

17.

Gatter KC, Warnke RA (2002) Diffuse large cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JV (eds) Pathology and genetics of tumors of haematopoietic and lymphoid tissues. IARC, Lyon, pp 171–174

18.

Neuwelt EA, Goldman DL, Dahlborg SA, Crossen J, Ramsey F, Roman-Goldstein S, Braziel R, Dana B (1991) Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 9:1580–1590PubMed

19.

Cher L, Glass J, Harsh GR, Hochberg FH (1996) Therapy of primary central nervous system lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: preliminary results. Neurology 46:1757–1759PubMed

20.

Freilich RJ, Delattre JY, Monjour A, De Angelis LM (1996) Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 46:435–439PubMed

21.

Hoang-Xuan K, Chinot O, Frenay M, Taillandier L, Hildebrand J, Monjour A, van den Bent M, Sahmoud T, Poisson M, Delattre JY (1997) Chemotherapy alone as initial treatment of primary central nervous system. Neurology 48:A17CrossRef

22.

Sherman W, Balmaceda C, Nichols G, Mears G, Antman K (1997) Feasibility of 3 g/m² of intravenous methotrexate for primary central nervous system lymphoma. Neurology 48:A17–A18CrossRef

23.

Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinquely M, Cerati M, Milani M, Orvieto E, Sanchez J, Chevreau C, Dell’Oro S, Zucca E, Cavalli F (2003) Prognostic scoring system for primary CNS lymphoma: the International Extranodal Lymphoma Study Group Experience. J Clin Oncol 21:266–272. doi:10.1200/JCO.2003.09.139 PubMedCrossRef

24.

Helle TL, Britt RH, Golby TV (1984) Primary lymphoma of the central nervous system: clinicopathological study of experience at Stanford. J Neurosurg 60:94–103PubMedCrossRef

25.

Pollack IF, Lunsford LD, Flickinger JC, Dameshek HL (1989) Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma. Cancer 63:939–947. doi:10.1002/1097-0142(19890301)63:5<939::AID-CNCR2820630526>3.0.CO;2-VPubMedCrossRef

26.

Michalski JM, Garcia DM, Kase E, Griqsby PW, Simpson JR (1990) Primary central nervous system lymphoma: analysis of prognostic variables and patterns of treatment failure. Radiology 176:855–860PubMed

27.

Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, Treseler P, Berger M, McDermott M, Prados M, Karch J, Okada C, Hyun W, Parikh S, Haqq C, Shuman M (2006) Gene expression and angiotropism in primary CNS lymphoma. Blood 107:3716–3723. doi:10.1182/blood-2005-03-0897 PubMedCrossRef

28.

Buettner R, Mora LB, Jove R (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8:945–954PubMed

29.

Gao L, Zhang L, Hu J, Li F, Shao Y, Zhao D, Kalvakolanu DV, Kopecko DJ, Zhao X, Xu DQ (2005) Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo. Clin Cancer Res 11:6333–6341. doi:10.1158/1078-0432.CCR-05-0148

30.

Bissell MJ, Radisky DC, Rizki A, Weaver VM, Petersen OW (2002) The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation 70:537–546. doi:10.1046/j.1432-0436.2002.700907.x PubMedCrossRef

31.

Das S, Roth CP, Wasson LM, Vishwanatha JK (2007) Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer. Prostate 67:1550–1564. doi:10.1002/pros.20640 PubMedCrossRef

32.

Batchelor T, Carson K, O’Neill A, Grossman SA, Alavi J, New P, Hochberg F, Priet R (2003) Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 21:1044–1049. doi:10.1200/JCO.2003.03.036 PubMedCrossRef

33.

Herrlinger U, Kuker W, Uhl M, Blaicher H, Karnath H, Kanz L, Bamberg M, Weller M (2005) NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 57:843–847. doi:10.1002/ana.20495 PubMedCrossRef

34.

Harder H, Holtel H, Bromberg JE (2004) Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 62:544–547PubMed

35.

Chon B, Hochberg F, Loeffler J, Batchelor T (2001) Methotrexate reinduction in patients with relapsed primary central nervous system lymphoma. Neuro Oncol 3:356

36.

Reni M, Mason W, Zaja F, Franceschi E, Bernardi D, Dell’Oro S, Stelitano C, Candela M, Abbadessa A, Pace A, Bordonaro R, Latte G, Villa E, Ferreri AJ (2004) Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 40:1682–1688. doi:10.1016/j.ejca.2004.03.008 PubMedCrossRef

Title: Long-term survival in primary CNS lymphoma treated by high-dose methotrexate monochemotherapy: role of STAT6 activation as prognostic determinant
Authors: Seung-Ho Yang
Kun Soo Lee
Il Sup Kim
Jae Taek Hong
Jae Hoon Sung
Byung Chul Son
Sang Won Lee
Yong-Kil Hong
Publication date: 01-03-2009
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2009
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-008-9736-9

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Long-term survival in primary CNS lymphoma treated by high-dose methotrexate monochemotherapy: role of STAT6 activation as prognostic determinant

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

Melanocytoma in the orbital apex

A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)

Expression of HIF-1, galectin-3, cox-2 and Wilms tumor-1 protein in multiple schwannomas of the conus medullaris

Rosai-Dorfman disease manifesting as intracranial and intraorbital lesion

Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2′-deoxycytidine in glioma cells

Different pattern of expression of nestin in the non-specific form of dysembryoplastic neuroepithelial tumors compared to the simple and complex forms